D Dimer Testing Global Market Report 2024

The d dimer testing market size has grown strongly in recent years. It will grow from $1.38 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed in the historical period can be attributed to several factors, including the emergence and advancement of thrombosis research, enhancements in laboratory techniques facilitating d-dimer testing, the clinical validation of d-dimer as a significant marker in diagnosing clotting disorders, and a notable shift in diagnostic protocols favoring the utilization of d-dimer testing in medical assessments.

The d dimer testing market size is expected to see steady growth in the next few years. It will grow to $1.77 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The anticipated growth in the forecasted period can be linked to several factors, notably the rising population of elderly individuals, the expansion of point-of-care testing (POCT) methods, the integration of d-dimer testing with risk assessment algorithms, heightened awareness campaigns and educational initiatives, as well as regulatory guidance and standardization efforts in the field. Key trends expected in this forecasted period encompass the utilization of biomarker combinations to improve diagnostic capabilities, a strong emphasis on achieving rapid and accurate testing results, the integration of d-dimer testing in the management of COVID-19 cases, the development of remote monitoring and home-based testing kits, as well as a shift towards continuous monitoring and serial testing methodologies.

The anticipated increase in the prevalence of cancer is poised to be a significant driver for the growth of the d-dimer testing market. Cancer, characterized by uncontrolled proliferation of abnormal cells that can invade neighboring tissues or spread to other organs, necessitates effective diagnostic and monitoring tools. D-dimer testing plays a crucial role in the management of cancer patients, aiding in diagnosis, monitoring, and treatment, as well as assessing the risk of blood clot formation - a common complication in cancer. As of January 2022, research from the American Cancer Society indicates a substantial burden of cancer, with an anticipated 609,360 cancer deaths and 1.9 million new cancer cases in the US in 2022. The increasing prevalence of cancer, with about 1,670 fatalities each day, underscores the driving force behind the growth of the d-dimer testing market.

The rising frequency of surgical procedures is expected to further boost the growth of the d-dimer testing market. Surgical procedures, involving manual or instrumental techniques to treat various medical conditions, pose a risk of thrombotic events, making d-dimer testing crucial for postoperative monitoring. Early detection of complications through d-dimer testing can improve patient outcomes. As of April 2022, a report from the Aesthetic Society, a US-based organization of board-certified plastic surgeons, highlights a significant increase in surgical procedures, with a 54% rise and an average of 320 surgical procedures performed by plastic surgeons in 2021. The average cost of a typical surgical procedure also increased by 6% in 2021. This surge in demand for surgical procedures underscores the importance of d-dimer testing in postoperative care, driving the growth of the d-dimer testing market.

Major players in the d-dimer testing market are actively pursuing a strategic partnership approach to secure exclusive rights to d-dimer testing solutions, gaining a competitive advantage in the market. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. An illustrative example is the partnership between SphingoTec GmbH, a Germany-based biotechnology company, and Rivaara Labs Pvt Ltd., an India-based medical laboratory and healthcare company. Established in March 2022, this partnership grants Rivaara exclusive rights to market and distribute SphingoTec's point-of-care tests featuring innovative biomarkers in the Indian subcontinent. These biomarkers include proenkephalin (penKid) for kidney function assessment, bioactive adrenomedullin (bio-ADM) for endothelial function evaluation, and dipeptidyl peptidase 3 (DPP3) as a biomarker for cardiac depression. These pioneering markers, along with commonly used parameters such as procalcitonin, troponin, D-dimer, NT-proBNP, and TSH, enhance diagnostic capabilities.

Major companies in the d-dimer testing market are also focusing on developing innovative products, such as d-dimer controls, to cater to larger customer bases, increase sales, and boost revenue. D-dimer controls involve substances or samples with a known concentration of D-dimer, a fibrin degradation product. For example, in March 2021, Randox, a UK-based provider of clinical diagnostic solutions, launched Acusera D-Dimer Controls. This product stands out by providing a genuine third-party solution for D-dimer testing - a crucial investigation for blood clotting disorders. The control is specifically manufactured to ensure accurate and reliable D-dimer testing across various diagnostic systems. Notably, it comes in a liquid frozen format and boasts an impressive stability of 28 days when stored at 2ºC to 8ºC, enhancing its utility for precise and consistent patient testing. This focus on partnerships and innovative product development reflects a commitment to excellence and competitiveness in the d-dimer testing market.

In March 2023, Werfen S.A., a leading diagnostic company based in Spain, successfully acquired Immucor Inc. for a significant sum of $2 billion. This strategic acquisition was pursued by Werfen with the objective of broadening its range of products and reinforcing its standing within the global market for transfusion and transplantation diagnostics. The acquisition of Immucor Inc., a distinguished US-based manufacturer known for producing d-dimer test kits, encompassing enzyme-linked immunosorbent assay (ELISA) technology, as well as transfusion and transplant diagnostic products, is expected to provide Werfen with access to Immucor's extensive global presence and resources.

Major companies operating in the d dimer testing market report are Kaiser Foundation Health Plan Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Becton Dickinson And Company (BD), Laboratory Corporation, Quest Diagnostics Inc., bioMérieux SA, Beckman Coulter Inc., Quidel Corporation, QuidelOrtho Corporation, Sysmex Corporation, Horiba Ltd., Werfen SA, Helena Laboratories Corporation, Abcam plc, LumiraDx Limited, Sekisui Diagnostics LLC, Personalabs, Sekisui Diagnostics LLC, Diagnostica Stago S.A.S., RayBiotech Inc., CTK Biotech Inc., Diazyme Laboratories Inc., AdvaCare Pharma USA, UCP Biosciences Inc., Unbound Medicine Inc., AccuBioTech Co Ltd., Response Biomedical Corporation.

North America was the largest region in the D dimer testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the d dimer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the d dimer testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary categories of d-dimer testing encompass clinical laboratory tests and point-of-care tests. Clinical laboratory tests encompass a broad range of diagnostic procedures conducted on patient samples within laboratory settings. These tests involve various products such as analyzers, reagents, and consumables, employing methods such as enzyme-linked immunosorbent assay (ELISA), latex-enhanced immuno-turbidimetric assays, and others. They serve multiple applications including detecting conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), among others. These tests are utilized by various end-users including hospitals, academic and research institutes, diagnostic centers, and other medical facilities.

The d-dimer testing market research report is one of a series of new reports that provides d-dimer testing market statistics, including d-dimer testing industry global market size, regional shares, competitors with a d-dimer testing market share, detailed d-dimer testing market segments, market trends, and opportunities, and any further data you may need to thrive in the d-dimer testing industry. This d-dimer testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The d-dimer testing market consists of revenues earned by entities by providing services such as sample collection, sample processing, exclusion of blood clots, and risk assessment and stratification. The market value includes the value of related goods sold by the service provider or included within the service offering. The d-dimer testing market also includes sales of d-dimer assay kits, d-dimer rapid tests, automated d-dimer analyzers, and point-of-care test kits that are used in providing d-dimer testing services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.